New hope for aggressive lobular breast cancer: ivonescimab trial launches
NCT ID NCT07229417
First seen Nov 17, 2025 · Last updated Jun 15, 2026 · Updated 35 times
Summary
This study tests whether the drug ivonescimab can help control a rare and aggressive form of breast cancer called invasive lobular carcinoma that has spread and no longer responds to hormone therapy. About 29 adults with either hormone-receptor-positive or triple-negative disease will receive the drug and be monitored for side effects and tumor response. The goal is to find a new treatment option for patients who have few alternatives.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC INVASIVE LOBULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.